Novel immune checkpoint blocker approved for the treatment of advanced melanoma

Lorenzo Galluzzi; Guido Kroemer; Alexander Eggermont

doi:10.4161/21624011.2014.967147

Novel immune checkpoint blocker approved for the treatment of advanced melanoma

Lorenzo Galluzzi, Guido Kroemer, Alexander Eggermont

Research output: Contribution to journal › Editorial

32 Scopus citations

Original language	English
Pages (from-to)	e967147-1-e967147-5
Journal	Oncoimmunology
Volume	3
Issue number	11
DOIs	https://doi.org/10.4161/21624011.2014.967147
State	Published - Nov 2 2014
Externally published	Yes

Keywords

CTLA4
ipilimumab
Keytruda™
nivolumab
PD-1
Yervoy™

Access to Document

10.4161/21624011.2014.967147

Cite this

@article{7801a52dd88948fa939e405252f16ac8,

title = "Novel immune checkpoint blocker approved for the treatment of advanced melanoma",

keywords = "CTLA4, ipilimumab, Keytruda{\texttrademark}, nivolumab, PD-1, Yervoy{\texttrademark}",

author = "Lorenzo Galluzzi and Guido Kroemer and Alexander Eggermont",

year = "2014",

month = nov,

day = "2",

doi = "10.4161/21624011.2014.967147",

language = "English",

volume = "3",

pages = "e967147--1--e967147--5",

journal = "Oncoimmunology",

issn = "2162-4011",

publisher = "Landes Bioscience",

number = "11",

}

TY - JOUR

T1 - Novel immune checkpoint blocker approved for the treatment of advanced melanoma

AU - Galluzzi, Lorenzo

AU - Kroemer, Guido

AU - Eggermont, Alexander

PY - 2014/11/2

Y1 - 2014/11/2

KW - CTLA4

KW - ipilimumab

KW - Keytruda™

KW - nivolumab

KW - PD-1

KW - Yervoy™

UR - http://www.scopus.com/inward/record.url?scp=84921398753&partnerID=8YFLogxK

U2 - 10.4161/21624011.2014.967147

DO - 10.4161/21624011.2014.967147

M3 - Editorial

AN - SCOPUS:84921398753

SN - 2162-4011

VL - 3

SP - e967147-1-e967147-5

JO - Oncoimmunology

JF - Oncoimmunology

IS - 11

ER -

Novel immune checkpoint blocker approved for the treatment of advanced melanoma

Keywords

Access to Document

Other files and links

Fingerprint

Cite this